Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive vs Usual BP Control in Hypertensive Aortic Valve Disease Patients
NCT03666351Phase 4Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of losartan, amlodipine and chlorthalidone in hypertension (HTN) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Left Ventricular Mass at 24 months. Started Oct 2018; status: completed.
02
Drugs
losartanamlodipinechlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03666351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666351.